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Background. Statins and other cardiovascular medication possess antioxidant capacity. It was examined whether chronic use of
these medications protects from the development of ischemia-reperfusion (I/R) related complications after DIEP (Deep Inferior
Epigastric Perforator Free Flap) surgery. This paper contains a literature study on the antioxidant working mechanisms of
these drugs. Methods. Medical information of 134 DIEP patients (173 ﬂaps) was studied from their medical ﬁles. Patient and
operative characteristics were registered, as well as I/R related complications. Results. Of the group that didnot use statins, 16.3%
developed complications versus 30.8% amongst patients that did use these drugs (P = 0.29). Amongst patients that chronically
use other cardiovascular medication, 26.8% developed I/R related complications versus 14.4% of the patients without medication
(P = 0.10). Conclusions. Chronic use of statins or other cardiovascular medication didnot decrease the occurrence of I/R related
complications after DIEP surgery. Therefore, research should be aimed at evaluating short-term pre-treatment with statins.
1.Introduction
Neutrophil inﬂux and the formation of reactive oxygen spec-
ies (ROS) play an important role in the initiation of ische-
mia-reperfusion (I/R) damage. An early survey of registered
medication showed that many drugs possess antioxidant
capacity, which might contribute to their pharmacological
action [1]. Statins (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors) are inhibitors of sterol synthesis [2].
They block the conversion of HMG-CoA to mevalonate,
which is the rate-determining step in cholesterol production
[3]. Statins display a pleiotropic activity including anti-
atherosclerotic, antithrombotic, but also anti-inﬂammatory
and neuroprotective eﬀects [2, 4, 5]. They also exert antioxi-
dant eﬀects [4, 6]. All these eﬀects seem to be independent of
their cholesterol-lowering eﬀect [7, 8]. Animal studies have
shown a protective eﬀect by administration of statins pre-
viously to I/R. They demonstrated that pre-treatment with
statins for several days, reduces myocardial injury after I/R
[8–11]. Renal function and survival after renal I/R were im-
proved after short-term statin pre-treatment in rats [12, 13].
Improved graft function and decreased renal inﬂammation
were achieved after statin pre-treatment before renal trans-
plantation [14]. Furthermore, atorvastatin treatment for
10 days signiﬁcantly reduced infarct volume after cerebral
ischemia [15].
Other cardiovascular drugs also possess antioxidant ca-
pacity,forexample,ACE-inhibitors,calciumantagonists,an-
tiarrhythmic drugs, and β-adrenoceptor antagonists [1, 16].
ACEinhibitorshaveshowntodisplaycardioprotectiveeﬀects
through free radical scavenging [17, 18]. Furthermore, they2 Journal of Transplantation
display anti-inﬂammatory eﬀects. This is probably achieved
by preventing leukocyte adhesion [19]. These beneﬁcial ef-
fects were also demonstrated in I/R of rat liver [20]. Calcium
antagonists have also demonstrated protective eﬀects in I/R
oftheliver [21].Allthesestudies werecarried outinanimals;
little research has been performed in humans in this area.
Administration of statins or other cardiovascular medi-
cation would be a safe and simple method to protect pa-
tients who are undergoing a medical procedure from the
development of I/R damage. The Deep Inferior Epigastric
Perforator Free Flap (DIEP) operation is featured by I/R.
During this procedure, a tissue ﬂap is dissected from the
abdomen and transplanted to the patient’s thorax. The tissue
ﬂap has to endure around 60 minutes of ischemia. Although
this operation is usually successful, in 5–10% of the patients
(partial) ﬂap loss occurs. Flap failure after DIEP surgery is a
traumatic event for the patient, who already battled against
cancer.Flapfailurerepresentsanotherdisappointmentwhich
leaves the patient with less reconstructive options and the
knowledgeofhavingtoendureyetanotheroperation.There-
fore, much research is being performed in order to prevent
the eﬀects of I/R injury. In this study it was examined whe-
therchronicuseofstatinsorothercardiovascularmedication
protects from the development of I/R related complications
after DIEP surgery.
2.MaterialsandMethods
2.1. Population. The sample consisted of women that had
undergone breast amputation or mastectomy due to breast
cancer or in order to prevent breast cancer and underwent
breast reconstruction at the Department of Plastic and Re-
constructive Surgery in the Maastricht University Medical
Centre in The Netherlands between September 2004 and
June 2009. Medical information of 134 DIEP patients,
amongst whom 39 patients who underwent bilateral surgery,
was studied from their medical ﬁles.
2.2. Medical Information. Of every patient, the medical ﬁle
was studied for the following patient characteristics: age,
length, weight, smoking, and the use of medication. Further-
more, I/R related complications after DIEP surgery were re-
gistered (reexploration, necrosis, and (partial) ﬂap loss).
Data were processed anonymously and per DIEP ﬂap.
2.3. Statistics. With STATA random-eﬀects logistic regres-
sion,twostatisticalmodelswerecalculatedtoanswerbothre-
search questions. In each statistical model, the patient cha-
racteristics age, BMI, and smoking were included and in-
tegrated as covariates. For patients who underwent bilateral
DIEP surgery, statistical correction was performed. Signiﬁ-
cance was considered present at P ≤ 0.05, two tailed.
3. Results
In 13 of the 173 DIEP ﬂaps, statins were used (7.51%) and in
41 ﬂaps other cardiovascular drugs were taken (23.70%).
Table 1: patient characteristics per study group.
All Statin Cardiovascular
N (ﬂaps) 173 13 41
Age (yr) 47.67 58.31 53.93
BMI (kg2/m2) 27.17 28.40 28.60
Smoking (%) 12.72 0 2.44
Complication (%) 17.34 30.77 26.83
Patient characteristics are shown in Table 1.I n3 0F l a p s
(17.34%) I/R related complications developed.
Statistical analysis showed that the number of I/R related
complications after DIEP surgery hadnot decreased due to
chronic use of statins. Of the group that did not use statins
16.3% developed complications versus 30.8% amongst pa-
tients that did use these drugs (P = 0.29). Furthermore, a
nonsigniﬁcant increasing trend in the occurrence of com-
plications appeared after chronic use of other cardiovascular
medication; 14.4% of the patients without medication versus
26.8% of the patients using drugs (P = 0.10). Patient cha-
racteristics age, BMI, and smoking did not signiﬁcantly in-
ﬂuence the occurrence of complications in both regression
models. In 22 out of 173 DIEP ﬂaps, the patient smoked
(12.72%).
4. Discussion
4.1. The DIEP Flap As a Model of I/R. In this study, the DIEP
ﬂap was used as a clinical, human model of I/R. It has the
advantage of being visible and within reach, even after sur-
g e r y .T h e r e f o r e ,t h i sn e wm o d e li sw e l ls u i t e df o ra n a l y s i n g
I/R in humans over time. Furthermore, duration of ischemia
is relatively constant and patients are healthy, at the time of
surgery there is no active disease. Another beneﬁt that the
DIEP model oﬀers is that it is an autologous transplantation
and there is no interference of donor incompatibility. There-
fore, the isolated eﬀect of an intervention can be studied.
4.2. Statins. Statins exert their actions through several me-
chanisms. Through inhibition of the mevalonate pathway,
statins inhibit isoprenoid production [9]. Isoprenoids are
responsible for posttranslational modiﬁcation of many pro-
teins, amongst which is Rho [9]. Rho plays an important role
in inﬂammation by activating transcription factor nuclear
factor-kB and it also decreases endothelial production of
nitricoxide(NO)[9].ByinhibitingtheisoprenylationofRho
and Rho kinase, statins increase eNOS (endothelial nitric
oxide synthase) mRNA stability and thereby NO production
[3, 4, 7–9]. Statins may also directly activate eNOS through
protein kinase Akt activation [8, 12, 13, 22]. Statins activate
receptor tyrosine kinases and G-protein-coupled receptors,
thereby activating phosphoinositol-3 kinase, which conse-
quently activates the protein kinase Akt by phosphorylation
[8]. Next, Akt causes eNOS to be phosphorylated and NO
production to increase [9]. Increased availability of NO im-
proves endothelium function and blood ﬂow to the tissues
[23].Journal of Transplantation 3
Secondly, statin administration inhibits upregulation of
adhesion molecules, like VCAM-1, ICAM-1 and P-selectin
[9, 24]. Hereby, neutrophil rolling, adherence, and neutro-
phil inﬂux are reduced [25, 26]. This decreased expression
of adhesion molecules and PMN inﬁltration is thought to be
regulated through NO release from the endothelium [9, 26–
30]. However, how this occurs remains unclear. Some stud-
ies demonstrate that eNOS just functions as a trigger for
initiating protection, while iNOS (inducible nitric oxide syn-
thase) is the essential mediator in protection through phar-
macological preconditioning and is upregulated after statin
use [10, 11]. Other studies, on the other hand, show that
statins decrease iNOS expression [24, 30].
Researchshowedthattheprotectiveeﬀectsofstatintreat-
mentcouldalsobemediatedbyincreasedprostaglandinpro-
duction,whichisduetoanupregulationofcyclooxygenase-2
and other prostaglandin synthases [10]. Cyclooxygenase-2
is the enzyme that catalyses the rate-limiting step in prost-
aglandin synthesis. Prostaglandins can have beneﬁcial eﬀects
during I/R, like anti-inﬂammatory eﬀects, vasodilation, and
platelet disaggregation.
Furthermore, statins display antioxidant eﬀects. They are
exerted through many pathways, all resulting in decreased
ROS production. First, they inhibit NADPH oxidase, thereby
attenuating neutrophil respiratory burst [6]. Furthermore,
statins cause S-nitrosylation of thioredoxin, thereby increas-
ing its enzymatic activity and reducing intracellular ROS
production [31]. Reduction in ROS production is also achie-
ved by activation of the heme oxygenase-1 promotor in
endothelial cells [32]. Heme oxygenases convert heme to
biliverdin. Degradation products of heme have the capacity
to decrease superoxide anion production [9]. Superoxide
production can also be reduced by inhibiting tyrosine
phosphorylation in activated neutrophils [33]. Finally, sta-
tins downregulate the aldose reductase pathway, which is in-
volved in oxidative stress [14]. Aldose reductase competes
withglutathionereductaseforNADPH,causingadecreasein
reduced glutathione content. Subsequently, the sorbitol me-
tabolism produces NADH, which enables NADH oxidase to
produce more ROS [14]. By inhibiting the aldose reductase
pathway, statins thus reduce ROS production during I/R and
they increase antioxidant capacity by restoring tissue gluta-
t h i o n el e v e l s[ 25].
4.3. Cardiovascular Medication. T h ep r o t e c t i v ee ﬀects of car-
diovascularmedication arealsoestablishedthroughdiﬀerent
mechanisms. Calcium antagonists, angiotensin II, and ACE-
inhibitors increase blood ﬂow during reperfusion either by
vasodilation or through stimulation of angiogenesis [34].
Treatment with angiotensin II and captopril have been de-
monstratedtostimulateangiogenesisandtherebyinclinefree
ﬂap viability and vascularity [35]. Through activation of the
AT1 receptor, angiotensin II increases vascular endothelial
growth factor expression by vascular smooth muscle and en-
dothelial cellsand directly stimulates endothelial cellsto pro-
duce NO [35].
Furthermore, cardiovascular drugs can prevent ROS for-
mation. First, calcium antagonists inhibit the inﬂux of ca-
lcium during I/R [18]. In this process, the lack of ATP leads
to ATP-dependent calcium pump dysfunction, causing the
intracellular calcium level to increase. This calcium overload
triggers conversion of xanthine dehydrogenase to xanthine
oxidase, causing the production of ROS [21]. Thus, inhibit-
ing calcium inﬂux prevents ROS formation. β-adrenoceptor
antagonists also protect from I/R by attenuating calcium
inﬂux[16].Secondly,cardiovasculardrugspreventautoxida-
tion of catecholamines. The antihypertensive eﬀect of ACE-
inhibitors is related to inhibition of norepinephrine release
from peripheral sympathetic neurons [17]. In the presence
of oxygen and transition metals catecholamines could be au-
toxidized, leading to OH-radical formation [17]. ACE-
inhibitors attenuate OH-radical production by decreasing
the level of norepinephrine [17]. However, not all ACE in-
hibitors have radical scavenging properties. It is believed that
only ACE inhibitors containing a SH-group in particular
possess this capacity [17]. Enalapril, for example, is a non-
SH-group containing ACE inhibitor and displayed no pro-
tective eﬀects during I/R [18].
The last ROS preventing mechanism is attenuation of
neutrophil accumulation during late reperfusion [34]. Just
likestatins,calciumantagonistscaninhibitneutrophilinﬂux,
thereby decreasing ROS production from the respiratory
burst.
Other working mechanisms of cardiovascular medica-
tion do not prevent ROS formation, but increase free radical
scavenging properties. Some drugs do this by increasing the
antioxidant reserve [18]. Captopril, for instance, increased
SOD activity, but induced no changes in glutathione peroxi-
dase and catalase enzyme activity [18]. However, it signiﬁ-
cantly attenuated lipid peroxidation [18]. Stobadine, a pyri-
doindole derivative that displays cardioprotective and anti-
arhythmical eﬀects, showed a protective eﬀect during I/R by
increasing the glutathione peroxidase activity and the total
antioxidant capacity [36]. ACE inhibitors and calcium an-
tagonists, especially the dihydropyridines, possess radical
scavenging properties and prevent ROS formation. They de-
creasebradykinindegradation,stimulatingeNOStoproduce
NO [19, 34]. NO may act as an antioxidant itself and also
prevents activation of polymorphonuclear leukocytes, there-
by decreasing the amount of ROS [19]. The increased brady-
kinin activity stimulates NO and prostacyclin production,
causing vasodilation too [18].
4.4. Results of This Study. Whether chronic statin treatment
oﬀers protective eﬀects in patients undergoing I/R-during
surgical procedures, remains unclear. Although some studies
demonstrated a decrease in C-reactive protein, plasma ad-
hesion molecule levels and cytokine levels [29, 37–40], other
studies could not conﬁrm these ﬁndings [41, 42]. And whe-
ther these changes result in a clinical beneﬁt, like a decrease
in I/R related complications, is not clear either. Pascual et al.
demonstrated a decrease in early complications after coro-
nary artery bypass grafting, but these beneﬁcial eﬀects only
occurred in patients with a positive troponin T status [41].
This beneﬁcial eﬀect might be caused by an eﬀect on athero-
sclerotic plaques or cholesterol level rather than a general
antioxidantoranti-inﬂammatorymechanism.Pattietal.and4 Journal of Transplantation
the study of Pasceri and colleagues both demonstrated a de-
crease in postprocedural complications after statin use [42,
43]. However, this was achieved after short-term pre-treat-
ment (7 days). An animal study showed that short-term sta-
tin administration could have protective eﬀects, while these
eﬀects are absent after chronic statin treatment [44].
There is little evidence proving a clinical protective eﬀect
of chronic statin use. Our study could not demonstrate a be-
neﬁcial eﬀect either. Chronic use of statins did not decrease
the occurrence of I/R related complications after DIEP sur-
gery. Unfortunately, the group that endured statin pre-treat-
ment was small (13 ﬂaps). There are studies demonstrating
evidence that short-term pre-treatment with statins could be
eﬀective in preventing I/R injury. Possibly the body adapts
to chronic statin use, thereby compensating the beneﬁcial
eﬀects of statins on I/R. Therefore, further research has to be
aimed at evaluating the eﬀects of short-term pre-treatment
with statins before I/R.
Theuseofcardiovascularmedicationevenshowedamild
increaseinthenumberofcomplications.Inthiscategorydif-
ferent types of drugs have been included. The eﬀects of these
d r u g so nt h ep r o c e s so fI / Ra r ed i ﬀerent. Some drugs might
not have a protective eﬀect at all, like non-SH-group con-
tainingACEinhibitors.Itispossiblethatastudyinwhichthe
diﬀerent types of cardiovascular drugs are studied separately,
shows a diﬀerent result. However, in our study no distinction
was made because groups would be small due to the large
variety of cardiovascular medications and because many
patients use multiple types of drugs.
Furthermore, patients in this study that use statins or
othercardiovasculardrugsdothisbasedonamedicalindica-
tion. This means all patients in the statin and cardiovascular
group suﬀer from hypertension or dyslipidemia, no patients
displayedcardiovasculardisease.Probably,thedecreasedvas-
cular condition and perfusion of these patients is the reason
for the increased risk of complications. The beneﬁcial eﬀects
of these drugs as described in the literature are probably
occurring, but are not strong enough to compensate for the
deleterious vascular condition of these DIEP patients. The
same accounts for the statin group in our study.
We had the idea to study whether a beneﬁcial eﬀect of
chronic use of statins or other cardiovascular medication
could be demonstrated from a medical ﬁle study in DIEP
patients, but unfortunately this was not the case. The main
disadvantage of this study is its observational, retrospec-
tive design. However, it demonstrated the probability that
chronic treatment with statins and other cardiovascular me-
dication inﬂuences the occurrence of I/R related compli-
cations and thereby gave important directions for further
research. Because there is ample literature demonstrating
evidence that short-term pre-treatment with statins could be
eﬀective in preventing I/R injury, future research should be
aimed at short-term pre-treatment instead of chronic use.
Ideally, this would be performed as an intervention study in
which these drugs are administered for a short period to
healthy patients undergoing I/R.
In conclusion, this study failed to demonstrate a protec-
tive eﬀect from the chronic use of statins or other cardio-
vascular medication on the eﬀects of I/R. However, there is
evidence demonstrating beneﬁcial eﬀects from short-term
pre-treatment with statins. Further research in this area
should therefore be focussed on short-term premedication
with statins. The most important feature in this study is the
use of the DIEP operation as a human model of I/R. In con-
trast to other models, this new, clinical model is well suited
for analysing I/R in humans over time because the DIEP ﬂap
remains within reach after surgery and interference of donor
incompatibility is avoided.
Disclosure
There are no funds supporting our work and no ﬁnancial be-
neﬁts. No authors have any ﬁnancial or personal relation-
ships with other people or organisations that could inﬂuence
our work.
Acknowledgment
This paper was presented at the fall congress of the Dutch
Society of Plastic Surgery in October 2009.
References
[1] A. Bast, “Antioxidant pharmacotherapy,” Drug News and Per-
spectives, vol. 7, no. 8, pp. 465–472, 1994.
[2] P.Urban,M.Pavlikova,M.Sivonovaetal.,“Molecularanalysis
of endoplasmic reticulum stress response after global fore-
brain ischemia/reperfusion in rats: eﬀect of neuroprotectant
simvastatin,” Cellular and Molecular Neurobiology, vol. 29, no.
2, pp. 181–192, 2009.
[3] S. Sharyo, N. Yokota-Ikeda, M. Mori et al., “Pravastatin im-
proves renal ischemia-reperfusion injury by inhibiting the
mevalonate pathway,” Kidney International,v o l .7 4 ,n o .5 ,p p .
577–584, 2008.
[4] O. Szarszoi, J. Maly, P. Ostadal et al., “Eﬀect of acute and
chronic simvastatin treatment on post-ischemic contractile
dysfunction in isolated rat heart,” Physiological Research, vol.
57, no. 5, pp. 793–796, 2008.
[5] A. Matsuki, A. Igawa, T. Nozawa et al., “Early administration
of ﬂuvastatin, but not at the onset of ischemia or reperfusion,
attenuates myocardial ischemia-reperfusion injury through
the nitric oxide pathway rather than its antioxidant property,”
Circulation Journal, vol. 70, no. 12, pp. 1643–1649, 2006.
[ 6 ] B .V .N a i d u ,S .M .W o o l l e y ,A .S .F a r i v a r ,R .T h o m a s ,C .F r a g a ,
and M. S. Mulligan, “Simvastatin ameliorates injury in an ex-
perimental model of lung ischemia-reperfusion,” Journal of
Thoracic and Cardiovascular Surgery, vol. 126, no. 2, pp. 482–
489, 2003.
[ 7 ]R .M e r l a ,I .N .D a h e r ,Y .Y e ,B .F .U r e t s k y ,a n dY .B i r n b a u m ,
“Pretreatment with statins may reduce cardiovascular mor-
bidity and mortality after elective surgery and percutaneous
coronary intervention: clinical evidence and possible underly-
ing mechanisms,” American Heart Journal, vol. 154, no. 2, pp.
391–402, 2007.
[8] S. Wolfrum, A. Dendorfer, M. Schutt et al., “Simvastatin acu-
tely reduces myocardial reperfusion injury In Vivo by activat-
ing the phosphatidylinositide 3-kinase/Akt pathway,” Journal
of Cardiovascular Pharmacology, vol. 44, no. 3, pp. 348–355,
2004.Journal of Transplantation 5
[9] D.G.WrightandD.J.Lefer,“Statinmediatedprotectionofthe
ischemic myocardium,” Vascular Pharmacology, vol. 42, no. 5-
6, pp. 265–270, 2005.
[10] Y. Birnbaum, Y. Ye, S. Rosanio et al., “Prostaglandins mediate
the cardioprotective eﬀects of atorvastatin against ischemia-
reperfusion injury,” Cardiovascular Research, vol. 65, no. 2, pp.
345–355, 2005.
[11] Y. Birnbaum, T. Ashitkov, B. F. Uretsky, S. Ballinger, and
M. Motamedi, “Reduction of infarct size by short-term
pretreatment with atorvastatin,” Cardiovascular Drugs and
Therapy, vol. 17, no. 1, pp. 25–30, 2003.
[12] N. Yokota, M. O’Donnell, F. Daniels et al., “Protective eﬀect of
HMG-CoA reductase inhibitor on experimental renal ische-
mia-reperfusion injury,” American Journal of Nephrology, vol.
23, no. 1, pp. 13–17, 2003.
[13] M. Joyce, C. Kelly, D. Winter, G. Chen, A. Leahy, and D.
Bouchier-Hayes, “Pravastatin, a 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor, attenuates renal injury in an
experimental model of ischemia-reperfusion,” Journal of Sur-
gical Research, vol. 101, no. 1, pp. 79–84, 2001.
[14] U.Gottmann, P.T.Brinkkoetter,S. Hoeger etal.,“Atorvastatin
donor pretreatment prevents ischemia/reperfusion injury in
renaltransplantationinrats:possibleroleforaldose-reductase
inhibition,” Transplantation, vol. 84, no. 6, pp. 755–762, 2007.
[15] S. H. Lee, Y. H. Kim, Y. J. Kim, and B. W. Yoon, “Atorvastatin
enhances hypothermia-induced neuroprotection after stroke,”
Journal of the Neurological Sciences, vol. 275, no. 1-2, pp. 64–
68, 2008.
[16] J. P. Wood, K. G. Schmidt, J. Melena, G. Chidlow, H. Allmeier,
a n dN .N .O s b o r n e ,“ T h eβ-adrenoceptor antagonists meti-
pranololandtimololareretinalneuroprotectants:comparison
with betaxolol,” Experimental Eye Research,v o l .7 6 ,n o .4 ,p p .
505–516, 2003.
[17] T.ObataandY.Yamanaka, “Protectiveeﬀect ofimidaprilat,an
angiotensin-converting enzyme inhibitor on ·OH generation
in rat myocardium,” Biochimica Et Biophysica Acta, vol. 1472,
no. 1-2, pp. 62–70, 1999.
[18] B. Anderson, N. Khaper, A. K. Dhalla, and P. K. Singal, “Anti-
free radical mechanisms in captopril protection against reper-
fusion injury in isolated rat hearts,” Canadian Journal of Ca-
rdiology, vol. 12, no. 10, pp. 1099–1104, 1996.
[19] C. Kupatt, H. Habazettl, S. Zahler et al., “ACE-inhibition pre-
vents postischemic coronary leukocyte adhesion and leuko-
cyte-dependent reperfusion injury,” Cardiovascular Research,
vol. 36, no. 3, pp. 386–395, 1997.
[20] S. Padrissa-Alt´ es, R. Franco-Gou, O. Boillot et al., “Eﬀect of
angiotensin II and bradykinin inhibition in rat reduced-size
liver transplantation,” Liver Transplantation,v o l .1 5 ,n o .3 ,p p .
313–320, 2009.
[21] R. E. Chavez-Cartaya, G. P. Desola, P. Ramirez-Romero, R. Y.
Calne, and N. V. Jamieson, “Ischemia and reperfusion injury
of the rat liver: the role of nimodipine,” Journal of Surgical Re-
search, vol. 60, no. 1, pp. 199–206, 1996.
[22] V.Prinz,U.Laufs,K.Gertzetal.,“Intravenousrosuvastatinfor
acute stroke treatment: an animal study,” Stroke,v o l .3 9 ,n o .2 ,
pp. 433–438, 2008.
[23] M. G. van den Heuvel, W. A. Buurman, A. Bast, and R. R. W.
van der Hulst, “Review: ischaemia-reperfusion injury in ﬂap
surgery,” Journal of Plastic, Reconstructive and Aesthetic Sur-
gery, vol. 62, no. 6, pp. 721–726, 2009.
[24] F. Gueler, S. Rong, J. K. Park et al., “Postischemic acute renal
failure is reduced by short-term statin treatment in a rat
model,” Journal of the American Society of Nephrology, vol. 13,
no. 9, pp. 2288–2298, 2002.
[25] V. H. Ozacmak, H. Sayan, A. A. Igdem, A. Cetin, and I.
D. Ozacmak, “Attenuation of contractile dysfunction by ator-
vastatin after intestinal ischemia reperfusion injury in rats,”
European Journal of Pharmacology, vol. 562, no. 1-2, pp. 138–
147, 2007.
[26] R. Scalia, M. E. Gooszen, S. P. Jones et al., “Simvastatin exerts
both anti-inﬂammatory and cardioprotective eﬀects in apo-
lipoprotein E-deﬁcient mice,” Circulation, vol. 103, no. 21, pp.
2598–2603, 2001.
[27] Y. Ikeda, L. H. Young, and A. M. Lefer, “Rosuvastatin, a new
HMG-CoA reductase inhibitor, protects ischemic reperfused
myocardium in normocholesterolemic rats,” Journal of Car-
diovascular Pharmacology, vol. 41, no. 4, pp. 649–656, 2003.
[28] A. M. Lefer, B. Campbell, Y. K. Shin, R. Scalia, R. Hayward,
andD.J.Lefer,“Simvastatinpreservestheischemic-reperfused
myocardiuminnormocholesterolemicrathearts,”Circulation,
vol. 100, no. 2, pp. 178–184, 1999.
[29] M. Chello, P. Mastroroberto, G. Patti et al., “Simvastatin at-
tenuates leucocyte-endothelial interactions after coronary re-
vascularisation with cardiopulmonary bypass,” Heart, vol. 89,
no. 5, pp. 538–543, 2003.
[30] P. D. Napoli, A. A. Taccardi, A. Grilli et al., “Chronic treat-
ment with rosuvastatin modulates nitric oxide synthase ex-
pression and reduces ischemia-reperfusion injury in rat
hearts,” Cardiovascular Research, vol. 66, no. 3, pp. 462–471,
2005.
[31] M.R.Gholami,F.Abolhassani,P.Pasbakhshetal.,“Theeﬀects
of simvastatin on ischemia-reperfusion injury of sciatic nerve
in adult rats,” E u r o p e a nJ o u r n a lo fP h a r m a c o l o g y , vol. 590, no.
1–3, pp. 111–114, 2008.
[32] F. Gueler, J. K. Park, S. Rong et al., “Statins attenuate ische-
mia-reperfusion injury by inducing heme oxygenase-1 in in-
ﬁltrating macrophages,” American Journal of Pathology, vol.
170, no. 4, pp. 1192–1199, 2007.
[33] J. P. Dillon, A. J. Laing, J. R. Chandler, J. H. Wang, A. McGuin-
ness, and H. P. Redmond, “Pravastatin attenuates tourniquet-
induced skeletal muscle ischemia reperfusion injury,” Acta
Orthopaedica, vol. 77, no. 1, pp. 27–32, 2006.
[34] A. V. Gourine, J. Pernow, D. M. Poputnikov, and P. O. Sj¨ oq-
uist, “Calcium antagonist clevidipine reduces myocardial re-
perfusion injury by a mechanism related to bradykinin and
nitric oxide,” Journal of Cardiovascular Pharmacology, vol. 40,
no. 4, pp. 564–570, 2002.
[ 3 5 ]H .T u f a n ,B .M .Z a k i ,M .T e c d e r - U n a l ,S .R .E r d e m ,a n dG .
Take, “Angiotensin II captopril cotreatment augments angio-
genesis in abdominal skin ﬂap in rats,” Annals of Plastic
Surgery, vol. 58, no. 4, pp. 441–448, 2007.
[36] J. Necas, L. Bartosikova, L. Benes et al., “Inﬂuence of antioxi-
dant eﬀect of stobadine derivative in condition of kidney isch-
emia-reperfusion in a pre-clinical experiment (eﬀect in pro-
phylaxis),” Biomedical papers of the Medical Faculty of the Uni-
versity Palack´ y, Olomouc, Czechoslovakia, vol. 149, no. 2, pp.
385–388, 2005.
[37] M. Chello, A. Anselmi, C. Spadaccio et al., “Simvastatin in-
creases neutrophil apoptosis and reduces inﬂammatory reac-
tion after coronary surgery,” Annals of Thoracic Surgery, vol.
83, no. 4, pp. 1374–1380, 2007.
[38] M. Chello, G. Patti, D. Candura et al., “Eﬀects of atorvastatin
on systemic inﬂammatory response after coronary bypass sur-
gery,” Critical Care Medicine, vol. 34, no. 3, pp. 660–667, 2006.
[39] M. Chello, M. Carassiti, F. Agro et al., “Simvastatin blunts
the increase of circulating adhesion molecules after coronary6 Journal of Transplantation
artery bypass surgery with cardiopulmonary bypass,” Journal
of Cardiothoracic and Vascular Anesthesia, vol. 18, no. 5, pp.
605–609, 2004.
[40] J. K. Plenge, T. L. Hernandez, K. M. Weil et al., “Simvastatin
lowers C-reactive protein within 14 days: an eﬀect independ-
ent of low-density lipoprotein cholesterol reduction,” Circula-
tion, vol. 106, no. 12, pp. 1447–1452, 2002.
[41] D. A. Pascual, J. M. Arribas, P. L. Tornel et al., “Preoperative
statin therapy and troponin T predict early complications of
coronary artery surgery,” Annals of Thoracic Surgery, vol. 81,
no. 1, pp. 78–83, 2006.
[42] G. Patti, M. Chello, V. Pasceri et al., “Protection from proc-
edural myocardial injury by atorvastatin is associated with
lower levels of adhesion molecules after percutaneous coro-
nary intervention. Results from the ARMYDA-CAMS (ator-
vastatin for reduction of MYocardial damage during angio-
plasty-celladhesionmolecules)substudy,”JournaloftheAmer-
ican College of Cardiology, vol. 48, no. 8, pp. 1560–1566, 2006.
[43] V.Pasceri,G. Patti,A.Nusca, C.Pristipino,G.Richichi, andG.
D. Sciascio, “Randomized trial of atorvastatin for reduction
of myocardial damage during coronary intervention: results
from the ARMYDA (atorvastatin for reduction of MYocardial
damage during angioplasty) study,” Circulation, vol. 110, no.
6, pp. 674–678, 2004.
[44] K. Mensah, M. M. Mocanu, and D. M. Yellon, “Failure to
protect the myocardium against ischemia/reperfusion injury
after chronic atorvastatin treatment is recaptured by acute
atorvastatin treatment: a potential role for phosphatase and
tensin homolog deleted on chromosome ten?” Journal of the
American College of Cardiology, vol. 45, no. 8, pp. 1287–1291,
2005.